Effective Use of Tables and Figures in Clinical Manuscript Writing

Tables and figures are essential components of any scientific manuscript. They convey complex data in a simplified and digestible format, allowing readers to understand results quickly. In clinical trial documentation, visuals support narrative clarity and enhance the scientific rigor of the manuscript. This tutorial outlines how to create and format effective tables and figures for pharma professionals and clinical trial writers, ensuring compliance with global publication and regulatory standards.

Whether presenting stability data, trial outcomes, or adverse event breakdowns, visuals align your content with expectations from both journals and regulatory reviewers such as EMA.

Why Tables and Figures Matter in Manuscripts:

Well-designed tables and figures:

• Summarize complex data succinctly
• Improve reader comprehension
• Support claims made in the Results and Discussion sections
• Help reviewers and regulatory authorities evaluate findings efficiently

They are especially useful in Stability Studies and pharmacokinetic/pharmacodynamic analyses, where trends and variations need visual reinforcement.

When to Use Tables vs Figures:

Each visual format serves a different purpose:

• Tables: Use for presenting precise numerical values, comparisons, and structured datasets (e.g., demographic breakdown, AE listings, dosing schedule).
• Figures: Use to highlight trends, relationships, or differences (e.g., Kaplan-Meier curves, line graphs of stability data, bar charts of efficacy outcomes).

Balance the number of visuals. Overuse can overwhelm, while underuse can underrepresent critical findings.

Formatting Tables for Regulatory and Journal Standards:

Follow these formatting best practices for tables:

• Number sequentially (Table 1, Table 2, etc.) as per order of citation
• Include a descriptive title above each table
• Provide footnotes to explain abbreviations, symbols, or statistical significance
• Use consistent decimal places and units throughout
• Avoid merging cells or complex formatting — simplicity is key

Adopt style guides such as ICMJE, AMA, or specific journal templates. In submissions to ICH-aligned agencies, tables must also adhere to GMP documentation standards, particularly when embedded in regulatory CTD documents.

Best Practices for Figures in Clinical Manuscripts:

Figures must convey insights visually without distorting data. Consider the following:

1. Use clear legends and axis labels
2. Ensure all data points are visible and scales are appropriate
3. Color-code only if publishing guidelines allow
4. Provide figure titles and brief captions beneath the figure
5. Save high-resolution images (300 dpi or more) for submission

Types of commonly used figures include:

• Line graphs (e.g., response over time)
• Bar charts (e.g., endpoint comparison)
• Pie charts (e.g., AE distribution)
• Forest plots (e.g., subgroup analysis)
• Survival curves (e.g., Kaplan-Meier)

Use tools like GraphPad Prism, R, or Excel for creating scientific-quality visuals that conform to pharmaceutical validation standards.

Labeling and Referencing Tables and Figures:

Maintain consistency throughout the manuscript:

• Refer to each table or figure by number in the text (e.g., “see Table 3”)
• Avoid phrases like “the following table” — always specify the number
• Describe the key takeaways in the narrative, not just a restatement of the table
• Ensure placement close to first citation in the manuscript if possible

Keep titles concise and informative. For example: “Table 2. Treatment-Emergent Adverse Events by System Organ Class (≥5%)”.

Checklist for Visual Data Compliance:

Ensure all visuals meet both publication and regulatory expectations:

• Numbered sequentially and cited in order
• Descriptive captions and legends
• Consistent font size, layout, and terminology
• No duplication of data across text and visuals
• Graphics adhere to pharmaceutical compliance norms (e.g., traceability of values)

Common Pitfalls in Tables and Figures:

• Overly complex visuals that confuse rather than clarify
• Inconsistent abbreviations or data formatting
• Redundant tables and figures showing the same data
• Lack of units, unclear labels, or truncated values
• Improper scaling or omission of confidence intervals

Use a quality review checklist to ensure consistency during CSR or manuscript development phases.

Using Templates and SOPs for Table and Figure Creation:

Standard operating procedures streamline visual consistency across documents. Refer to templates from Pharma SOPs for guidance on tabular format, especially in repetitive documents like clinical study reports (CSRs) or investigator brochures.

Conclusion:

Tables and figures enhance the clarity, readability, and impact of scientific manuscripts. When used correctly, they serve as powerful tools for clinical trial professionals to present their findings accurately and persuasively. By following structured best practices — from formatting and labeling to ethical representation and regulatory compliance — pharma professionals can ensure their manuscripts are ready for both peer review and regulatory scrutiny.

Always remember, visuals are not just supportive content — they are evidence. Present them with as much care and precision as you would the manuscript’s narrative.

Visualizing Survival Data in Clinical Trials: How to Use Graphs Effectively

Graphical representation of survival data is essential for communicating the results of clinical trials. While statistical models like the Cox proportional hazards model and log-rank tests provide the numbers, visualizing survival through curves and charts brings the data to life, helping clinicians, regulators, and sponsors interpret outcomes quickly and clearly.

This tutorial explains how to represent survival data graphically using standard tools like Kaplan-Meier plots, hazard functions, and survival probability charts. You’ll also learn how to annotate and format these visuals to meet the expectations of audiences such as EMA reviewers, DSMBs, and publication standards.

Why Graphical Representation Matters

In clinical trials—especially oncology, cardiovascular, and infectious disease studies—outcomes are often time-to-event based. These require not just statistical reporting but visual clarity:

• Highlighting survival differences between groups
• Visualizing the impact of censoring
• Showing delayed treatment effects
• Communicating the timing of divergence in survival

Properly constructed survival graphs support GMP audit documentation and regulatory submissions.

Kaplan-Meier (KM) Survival Curves

The Kaplan-Meier curve is the most commonly used graphical tool in survival analysis. It estimates the probability of survival over time, adjusting for censored subjects.

Key Features of a KM Plot:

• X-axis: Time (days, months, or years)
• Y-axis: Survival probability (0 to 1)
• Stepwise curve: Drops at each event occurrence
• Tick marks: Represent censored observations

Kaplan-Meier plots can display multiple groups (e.g., treatment vs. control) on the same chart, allowing visual comparison of survival trends.

How to Create KM Plots

1. Define the time-to-event variable and censoring indicator
2. Use statistical software such as R (survfit()), SAS (PROC LIFETEST), or Python (lifelines package)
3. Plot survival curves with group-wise color coding
4. Add confidence bands if needed (95% CI)
5. Annotate median survival times and significant p-values

KM curves must be accompanied by a number-at-risk table below the plot for proper interpretation.

Visualizing Hazard Functions

While KM plots show the probability of survival, hazard functions display the instantaneous rate of experiencing an event at a given time.

• Hazard rate: Useful for understanding treatment risks over time
• Smoothed hazard estimates: Can reveal treatment effects not obvious in KM plots

Hazard plots are often used in exploratory analysis to assess whether the proportional hazards assumption holds, which is essential when interpreting results from a Cox regression model.

Cumulative Incidence and Competing Risks Plots

In studies with multiple types of events (e.g., death from different causes), cumulative incidence functions (CIF) are plotted to depict the probability of a specific event type over time, accounting for competing risks.

These graphs are particularly important in hematologic malignancies, transplant trials, or COVID-19 research where multiple outcome types exist.

Best Practices for Graphing Survival Data

1. Label axes clearly: Use time units and survival probabilities
2. Use distinct line styles or colors: For treatment arms or covariate strata
3. Include number-at-risk tables: Beneath the X-axis for each group
4. Display censoring marks: As vertical ticks
5. Use a consistent time origin: E.g., randomization or treatment start
6. Annotate with key statistics: Median survival, p-values, hazard ratios

These visualizations support stability-focused documentation strategies, like those promoted on Stability Studies, especially when analyzing long-term clinical impact.

Example: KM Curve for a Lung Cancer Trial

In a non-small cell lung cancer (NSCLC) trial, KM plots were created comparing Drug A vs. standard chemotherapy. The treatment group curve diverged from control at 6 months, with median survival of 14.6 vs. 11.2 months. Log-rank test p = 0.03. Hazard ratio = 0.74 (95% CI: 0.59–0.94). These were annotated on the plot for regulatory submission to CDSCO.

Advanced Visual Techniques

• Stratified KM plots: Show results across multiple strata (e.g., biomarker subgroups)
• Time-varying hazard plots: Useful when hazard ratios are not proportional
• Overlay curves with risk difference or cumulative hazard: For in-depth understanding
• Forest plots: Visualize subgroup HRs from Cox model

Common Pitfalls to Avoid

• Omitting censoring indicators (tick marks)
• Truncating axes too early or late
• Failing to include risk tables
• Overcrowding graphs with too many strata
• Ignoring proportional hazard violations in interpretation

Using Graphs in Reports and Publications

Graphs should be exportable to high-resolution formats (PNG, PDF, EPS) and follow journal or regulatory formatting standards. Always pair visuals with tables and statistical summaries in Clinical Study Reports (CSRs).

Use validated graphical tools for compliance and traceability.

Conclusion: Mastering Graphical Survival Analysis

Effective graphical representation of survival data is more than just generating plots—it’s about delivering clinical insight with clarity and rigor. By using Kaplan-Meier plots, hazard functions, and incidence charts wisely, trial professionals can make survival outcomes more understandable and regulatory reviews more efficient. Stick to best practices, validate assumptions, and ensure your graphics communicate as powerfully as your statistics.